Poland· PL-100331308
Signifor
A pasireotide product containing pasireotidum, registered in Poland by Recordati Rare Diseases. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pasireotide is registered in 15 of 19 countries.
Countries holding a registration under ATC H01CB05 (pasireotide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Pasireotide · ATC H01CB05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pasireotide costs, country by country.
Normalised to the WHO defined daily dose (1.2 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pasireotide · price per daily dose (1.2 mg)
USD · FX 28 Sept 2026
- CH Switzerland$238.10
The record
At a glance
URPL (Poland)- Active substance
- Pasireotidum
- Manufacturer
- Recordati Rare Diseases
- Country
- Poland (PL)
- ATC code
- H01CB05
- ATC class
- Pasireotide
- Defined daily dose
- 1.2 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991200336
- gtin05909991200343
- gtin03663502002599
- gtin03663502003503
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
435 interactions on record for pasireotide.
Graded by severity as the source publishes them — 246 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pasireotide · interactions on record
435 records
- 246 severe
- 184 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pasireotide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSignifor 60 mgRecordati Rare Diseases
- SpainSIGNIFOR 60 MG POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLERecordati Rare Diseases
- United KingdomSignifor 60mg powder and solvent for suspension for injection vialsRecordati Rare Diseases UK Ltd
- IcelandSigniforRecordati Rare Diseases*
- NorwaySigniforRecordati Rare Diseases
- SwedenSignifor 60 mg Pulver och vätska till injektionsvätska, suspensionRecordati Rare Diseases
- NetherlandsSignifor 0,3 mg oplossing voor injectieRecordati Rare Diseases
- SwitzerlandSignifor 0.3 mg/1 ml, InjektionslösungRECORDATI AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Signifor
- Liechtenstein · Signifor
- Norway · Signifor
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d9cdb073-cd06-4ebd-aa6a-6ba70b50a208 GET /v1/drugs/d9cdb073-cd06-4ebd-aa6a-6ba70b50a208?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania zawiesiny do wstrzykiwań",
"source": "urpl",
"strength": "60 mg",
"packaging": "05909991200336 ¦ Rp ¦ Skasowane ¦ EU/1/12/753/16 ¦ 105607\n1 fiol. proszku + 1 amp.-strzyk. 2 ml rozp. + 1 igła + 1 łącznik fiolki\n05909991200343 ¦ Rp ¦ EU/1/12/753/017 ¦ 105608\n3 fiol. 60 mg proszku ¦ 3 igły + 3 łączniki fiolki ¦ 3 amp.-strzyk. 2 ml rozp.\n03663502002599 ¦ Rp ¦ EU/1/12/753/16 ¦ 141730\n1 fiol. 60 mg proszku ¦ 1 igła + 1 łącznik fiolki ¦ 1 amp.-strzyk. 2 ml rozp.\n03663502003503 ¦ Rp ¦ EU/1/12/753/16 ¦ 153541\n1 fiol. 60 mg proszku ¦ 1 igła + 1 łącznik fiolki ¦ 1 amp.-strzyk. 2 ml rozp.",
"substance": "Pasireotidum 60 mg",
"common_name": "Pasireotidum",
"pl_product_id": "100331308",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about pasireotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.